130 related articles for article (PubMed ID: 9631932)
1. Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay.
Fraser AD; Meatherall R
Ther Drug Monit; 1998 Jun; 20(3):331-4. PubMed ID: 9631932
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
Fraser AD; Meatherall R
J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
[TBL] [Abstract][Full Text] [Related]
3. CEDIA dau Benzodiazepine screening assay: a reformulation.
Meatherall RC; Fraser AD
J Anal Toxicol; 1998; 22(4):270-3. PubMed ID: 9681328
[TBL] [Abstract][Full Text] [Related]
4. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
Darragh A; Snyder ML; Ptolemy AS; Melanson S
Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
[TBL] [Abstract][Full Text] [Related]
5. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
Fraser AD; Howell P
J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
[TBL] [Abstract][Full Text] [Related]
6. Urinary screening for alpha-OH triazolam by FPIA and EIA with confirmation by GC/MS.
Fraser AD; Bryan W; Isner AF
J Anal Toxicol; 1992; 16(6):347-50. PubMed ID: 1293398
[TBL] [Abstract][Full Text] [Related]
7. Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT d.a.u. benzodiazepine metabolite assay.
Fraser AD
J Anal Toxicol; 1987; 11(6):263-6. PubMed ID: 3323671
[TBL] [Abstract][Full Text] [Related]
8. [Cross-reactivity of Instant-View M-1 for detection of benzodiazepine-related drugs and their metabolites in urine].
Torikoshi A; Namera A; Arima Y; Toubou H; Tajima T; Shiraishi H; Nagao M
Chudoku Kenkyu; 2014 Mar; 27(1):33-8. PubMed ID: 24724359
[TBL] [Abstract][Full Text] [Related]
9. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
Dixon RB; Floyd D; Dasgupta A
Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
[TBL] [Abstract][Full Text] [Related]
10. Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity.
Fitzgerald RL; Herold DA
J Anal Toxicol; 1997; 21(1):32-5. PubMed ID: 9013289
[TBL] [Abstract][Full Text] [Related]
11. Urine benzodiazepine screening using Roche Online KIMS immunoassay with beta-glucuronidase hydrolysis and confirmation by gas chromatography- mass spectrometry.
Klette KL; Wiegand RF; Horn CK; Stout PR; Magluilo J
J Anal Toxicol; 2005 Apr; 29(3):193-200. PubMed ID: 15842763
[TBL] [Abstract][Full Text] [Related]
12. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
Pettersson Bergstrand M; Helander A; Hansson T; Beck O
Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
[TBL] [Abstract][Full Text] [Related]
13. Rapid determination of benzodiazepines, zolpidem and their metabolites in urine using direct injection liquid chromatography-tandem mass spectrometry.
Jeong YD; Kim MK; Suh SI; In MK; Kim JY; Paeng KJ
Forensic Sci Int; 2015 Dec; 257():84-92. PubMed ID: 26282513
[TBL] [Abstract][Full Text] [Related]
14. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: two techniques evaluated and modified for improved performance.
Beck O; Lafolie P; Hjemdahl P; Borg S; Odelius G; Wirbing P
Clin Chem; 1992 Feb; 38(2):271-5. PubMed ID: 1541010
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine.
DeRienz RT; Holler JM; Manos ME; Jemionek J; Past MR
J Anal Toxicol; 2008; 32(6):433-7. PubMed ID: 18652750
[TBL] [Abstract][Full Text] [Related]
16. Immunoassay detection of benzodiazepines and benzodiazepine metabolites in blood.
Huang W; Moody DE
J Anal Toxicol; 1995 Oct; 19(6):333-42. PubMed ID: 8926726
[TBL] [Abstract][Full Text] [Related]
17. Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids.
Berg JA; Schjøtt J; Fossan KO; Riedel B
Subst Abuse Rehabil; 2015; 6():131-9. PubMed ID: 26604854
[TBL] [Abstract][Full Text] [Related]
18. Comparison of assay methods for benzodiazepines in urine. A receptor assay, two immunoassays, and gas chromatography-mass spectrometry.
Nishikawa T; Ohtani H; Herold DA; Fitzgerald RL
Am J Clin Pathol; 1997 Mar; 107(3):345-52. PubMed ID: 9052386
[TBL] [Abstract][Full Text] [Related]
19. Comparison of four immunoassays for the detection of lorazepam in urine.
Meatherall R; Fraser AD
Ther Drug Monit; 1998 Dec; 20(6):673-5. PubMed ID: 9853986
[TBL] [Abstract][Full Text] [Related]
20. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study.
Schwettmann L; Külpmann WR; Vidal C
Clin Chem Lab Med; 2006; 44(4):479-87. PubMed ID: 16599844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
